NewLimit
Jacob Kimmel is a co-founder and Head of Research at NewLimit, where efforts focus on developing epigenetic reprogramming medicines since March 2022. Previously, Kimmel served as a Principal Investigator at Calico Life Sciences, leading a computational and experimental biology laboratory tackling aging and age-related diseases from May 2018 to March 2022. Working at Calico, Kimmel also contributed as a Computational Fellow and Data Scientist, utilizing a blend of computational and experimental techniques. Academic credentials include a Ph.D. in Developmental & Stem Cell Biology from the University of California, San Francisco, where Kimmel conducted research on stem cell decision-making. A brief internship at IBM allowed for the application of deep learning methods in cell engineering.
This person is not in any teams
NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.